Therefore, a study has used in vitro (tumor cell lines, patient-derived cell cultures) and in vivo (genetically engineered mouse models and PDXs) neuroblastoma models to assess the treatment efficacy of combining the ALK (anaplastic lymphoma kinase) inhibitor lorlatinib with the MDM2 (murine double minute clone 2) inhibitor (idasanutlin) for ALK-aberrant neuroblastoma.185. The gene discussed is ALK; the disease is neuroblastoma.